R&D and productivity in the US and the EU: Sectoral specificities and differences in the crisis

被引:39
|
作者
Castellani, Davide [1 ]
Piva, Mariacristina [2 ]
Schubert, Torben [3 ,4 ]
Vivarelli, Marco [5 ,6 ,7 ]
机构
[1] Univ Reading, Henley Business Sch, Reading, Berks, England
[2] Univ Cattolica Sacro Cuore, Dept Econ Policy, Piacenza, Italy
[3] Lund Univ, CIRCLE, Lund, Sweden
[4] Fraunhofer ISI, Karlsruhe, Germany
[5] Univ Cattolica Sacro Cuore, Dept Econ Policy, Milan, Italy
[6] UNU MERIT, Maastricht, Netherlands
[7] IZA, Bonn, Germany
关键词
R&D; Productivity; Economic crisis; US; EU; HIGH-TECH SECTORS; INFORMATION TECHNOLOGY; DEVELOPMENT EXPENDITURE; DEVELOPMENT INVESTMENT; MANAGEMENT-PRACTICES; INNOVATIVE FIRMS; EUROPE; IMPACT; GROWTH; SKILLS;
D O I
10.1016/j.techfore.2018.10.001
中图分类号
F [经济];
学科分类号
02 ;
摘要
Using data on the US and EU top R&D spenders from 2004 until 2012, this paper investigates the sources of the US/EU productivity gap. We find robust evidence that US firms have a higher capacity to translate R&D into productivity gains (especially in the high-tech macro sector), and this contributes to explaining the higher productivity of US firms. Conversely, EU firms are more likely to achieve productivity gains through capital embodied technological change, at least in the medium-and low-tech macro sectors. Our results also show that the US/EU productivity gap has worsened during the crisis period, as the EU companies have been more affected by the economic crisis in their capacity to translate R&D investments into productivity. Based on these findings, we make a case for a learning-based and selective R&D funding, which, instead of purely aiming at stimulating higher R&D expenditures, works on improving the firms' capabilities to transform R&D into productivity gains.
引用
收藏
页码:279 / 291
页数:13
相关论文
共 50 条
  • [1] The productivity crisis in pharmaceutical R&D
    Pammolli, Fabio
    Magazzini, Laura
    Riccaboni, Massimo
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2011, 10 (06) : 428 - 438
  • [2] The productivity crisis in pharmaceutical R&D
    Fabio Pammolli
    Laura Magazzini
    Massimo Riccaboni
    [J]. Nature Reviews Drug Discovery, 2011, 10 : 428 - 438
  • [3] Sectoral productivity growth and R&D spillovers in the Netherlands
    Jacobs, B
    Nahuis, R
    Tang, PJG
    [J]. ECONOMIST-NETHERLANDS, 2002, 150 (02): : 181 - 210
  • [4] Sectoral Productivity Growth and R&D Spillovers in the Netherlands
    Bas Jacobs
    Richard Nahuis
    Paul J.G. Tang
    [J]. De Economist, 2002, 150 : 181 - 210
  • [5] US productivity in agriculture and R&D
    Fare, R.
    Grosskopf, S.
    Margaritis, D.
    [J]. JOURNAL OF PRODUCTIVITY ANALYSIS, 2008, 30 (01) : 7 - 12
  • [6] US coming to grips with R&D crisis
    Scott, WB
    [J]. AVIATION WEEK & SPACE TECHNOLOGY, 1997, 146 (07): : 22 - 23
  • [7] R&D intensity and firm performance-sectoral differences
    Kuittinen, Hanna
    Puumalainen, Kaisu
    Jantunen, Ari
    [J]. MANAGEMENT OF TECHNOLOGY INNOVATION AND VALUE CREATION, 2008, 2 : 39 - 53
  • [8] Decision of institutional cooperation on R&D Determinants and sectoral differences
    Ma Serrano-Bedia, Ana
    Concepcion Lopez-Fernandez, Ma
    Garcia-Piqueres, Gema
    [J]. EUROPEAN JOURNAL OF INNOVATION MANAGEMENT, 2010, 13 (04) : 439 - U92
  • [9] EU-US differences in the size of R&D intensive firms: do they explain the overall R&D intensity gap?
    Ortega-Argiles, Raquel
    Brandsma, Andries
    [J]. SCIENCE AND PUBLIC POLICY, 2010, 37 (06) : 429 - 441
  • [10] R&D and productivity: testing sectoral peculiarities using micro data
    Raquel Ortega-Argilés
    Lesley Potters
    Marco Vivarelli
    [J]. Empirical Economics, 2011, 41 : 817 - 839